Reference
- Pan H, Peto R, Henao-Restrepo
AM, et al. Repurposed Antiviral Drugs for Covid-19 - Interim WHO
Solidarity Trial Results. N Engl J Med, 2021, 384(6):497-511.
- Krammer F. SARS-CoV-2 vaccines
in development. Nature, 2020, 586(7830):516-27.
- Owen DR, Allerton CMN, Anderson
AS, et al. An oral SARS-CoV-2 Mpro inhibitor clinical candidate for
the treatment of COVID-19. Science, 2021, 374(6575):1586-93.
- Anand K, Ziebuhr J, Wadhwani P, et al. Coronavirus main proteinase
(3CLpro) structure: basis for design of anti-SARS drugs. Science,
2003, 300(5626):1763-7.
- Vangeel L, Chiu W, De Jonghe S, et al. Remdesivir, Molnupiravir and
Nirmatrelvir remain active against SARS-CoV-2 Omicron and other
variants of concern. Antiviral Res, 2022, 198(105252.
- Ullrich S, Ekanayake KB, Otting G, et al. Main protease mutants of
SARS-CoV-2 variants remain susceptible to nirmatrelvir. Bioorg Med
Chem Lett, 2022, 62(128629.
- Singh RSP, Toussi SS, Hackman F, et al. Innovative Randomized Phase I
Study and Dosing Regimen Selection to Accelerate and Inform Pivotal
COVID-19 Trial of Nirmatrelvir. Clin Pharmacol Ther, 2022,
112(1):101-11.
- Dal-Ré R, Becker SL, Bottieau E, et al. Availability of oral
antivirals against SARS-CoV-2 infection and the requirement for an
ethical prescribing approach. Lancet Infect Dis, 2022, 22(8):e231-e8.
- Sevrioukova IF, Poulos T L. Structure and mechanism of the complex
between cytochrome P4503A4 and ritonavir. Proc Natl Acad Sci U S A,
2010, 107(43):18422-7.
- Hammond
J, Leister-Tebbe H, Gardner A, et al. Oral Nirmatrelvir for High-Risk,
Nonhospitalized Adults with Covid-19. N Engl J Med, 2022,
386(15):1397-408.
- National Medical Products
Administration of China. Emergency conditional approval of Pfizer’s
COVID-19 therapy:nirmatrelvir tablet/ritonavir tablet combination
package (i.e. Paxlovid) importation registration [in Chinese].
Available at: https://www. nmpa. gov.
cn/yaowen/ypjgyw/20220212085753142. html. Accessed 27 April 2022.
- National Health Commission of
the People’s Republic of China. Diagnosis and treatment protocol for
COVID-19 (trial version 9) [in Chinese]. Available at: http://www.
nhc. gov. cn/cms-search/xxgk/getManuscriptXxgk. htm?id=b74ade1b
a4494583805a3d2e40093d88. Accessed 20 June 2022.
- Docherty AB, Harrison EM, Green CA, et al. Features of 20 133 UK
patients in hospital with covid-19 using the ISARIC WHO Clinical
Characterisation Protocol: prospective observational cohort study.
BMJ. 2020;369:m1985.
- Kim L, Garg S, O’Halloran A, et al. Risk Factors for Intensive Care
Unit Admission and In-hospital Mortality Among Hospitalized Adults
Identified through the US Coronavirus Disease 2019
(COVID-19)-Associated Hospitalization Surveillance Network
(COVID-NET). Clin Infect Dis, 2021, 72(9):e206-e14.
- Wu Z, McGoogan JM. Characteristics of and Important Lessons From the
Coronavirus Disease 2019 (COVID-19) Outbreak in China:Summary of a
Report of 72 314 Cases From the Chinese Center for Disease Control
and Prevention. JAMA, 2020, 323(13):1239-42.
- Zhang X, Zhang W, Chen S.
Shanghai’s life-saving efforts against the current omicron wave of the
COVID-19 pandemic. Lancet, 2022, 399(10340):2011-2.
- Drew RJ, O’Donnell S, LeBlanc
D, et al. The importance of cycle threshold values in interpreting
molecular tests for SARS-CoV-2. Diagn Microbiol Infect Dis, 2020,
98(3):115130.
- Zhang R, Liang H, Tang J. Negative Conversion Rate of SARS-CoV-2
Infection. JAMA Intern Med, 2021, 181(4):566.
- Li H, Gao M, You H, et al.
Association of Nirmatrelvir/Ritonavir Treatment on Upper Respiratory
Severe Acute Respiratory Syndrome Coronavirus 2 Reverse
Transcription-Polymerase Chain Reaction (SARS-Cov-2 RT-PCR) Negative
Conversion Rates Among High-Risk Patients With Coronavirus Disease
2019 (COVID-19). Clin Infect Dis, 2023, 76(3):e148-e54.
- Salvatore PP, Dawson P, Wadhwa
A, et al. Epidemiological Correlates of Polymerase Chain Reaction
Cycle Threshold Values in the Detection of Severe Acute Respiratory
Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis, 2021,
72(11):e761-e7.
- Rao SN, Manissero D, Steele VR,
et al. A Systematic Review of the Clinical Utility of Cycle Threshold
Values in the Context of COVID-19. Infect Dis Ther, 2020, 9(3):573-86.
- Stein SR, Ramelli SC, Grazioli
A, et al. SARS-CoV-2 infection and persistence in the human body and
brain at autopsy. Nature, 2022, 612(7941):758-63.
- Rodríguez-Grande C,
Adán-Jiménez J, Catalán P, et al. Inference of Active Viral
Replication in Cases with Sustained Positive Reverse Transcription-PCR
Results for SARS-CoV-2. J Clin Microbiol. 2021;59(2):e02277-20.Figure legendsFigure 1 The flow chart of the process used to screen eligible
patients.
Figure 2 Kaplan-Meier curve of primary outcome for
nirmatrelvir-ritonavir recipients versus matched control group
Figure 3 Change of RT-PCR Ct value for nirmatrelvir-ritonavir
recipients versus matched control group
Figure 4 Subgroup analysis of the mean difference of time to PCR
negative for nirmatrelvir-ritonavir recipients versus matched control
group
Figure 5 Subgroup analysis of the mean difference of time to viral
clearance for patients with different nirmatrelvir-ritonavir
initiation time versus matched control group